ストックスクリーナーアプリを入手
62.34
0.05%
-0.03
アフターアワーズ：
62.20
-0.14
-0.22%
Bristol Myers Squibb Co (BMY) 最新ニュース
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Mitsubishi UFJ Asset Management Co. Ltd. Has $204.06 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments - Kalkine Media
Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients - Benzinga
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer - BioPharma Dive
Bristol Myers: Biokin reports ‘positive’ results from Phase 3 study of iza-bren - TipRanks
Bristol Myers Squibb (BMY) Achieves Breakthrough in Breast Cance - GuruFocus
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce Biotech
Bristol Myers Squibb's Antibody Drug Achieves Success in China Trial - Intellectia AI
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug - Seeking Alpha
Primecap Management Co. CA Sells 850,330 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer - Business Wire
RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth - Finviz
Buybacks Report: Why is Bristol Myers Squibb Company Equity Right stock going upJuly 2025 Selloffs & Daily Profit Maximizing Tips - baoquankhu1.vn
2nd Circ. Skeptical Of Expanding Collectives' Borders - Law360
Why Bristol Myers Squibb Stock Topped the Market Today - AOL.com
Bristol-Myers Squibb Advances Pediatric Lymphoma Combo, Signaling Quiet Upside for BMY Investors - TipRanks
5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever - 24/7 Wall St.
Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal - San Diego Business Journal
RBC initiates Bristol-Myers Squibb stock at Sector Perform, $60 target - Investing.com
3 Reasons to Avoid BMY and 1 Stock to Buy Instead - Finviz
FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review - Finviz
Biopharma bites: Layoffs at BMS, Generate's IPO plans, Fortress's voucher sale…and more - FirstWord Pharma
FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation - Yahoo Finance UK
Bristol Myers Squibb discloses 247 more layoffs in NJ (updated) - NJBIZ
Bristol-Myers Touts Promising Data From Blood Disorder Study - Bitget
Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential - Finviz
Bristol-Myers Squibb’s New Rheumatoid Arthritis Trial: What Early Pipeline Moves Mean for BMY Investors - TipRanks
Bristol-Myers Squibb (BMY) Gets Price Target Raise by Piper Sand - GuruFocus
Bristol Myers Squibb (BMY) Reports Positive Phase 2 Trial Results for Reblozyl - GuruFocus
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 - Investing.com
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 By Investing.com - Investing.com India
Bristol Myers Squibb’s Reblozyl meets trial goals for alpha-thalassemia - Investing.com
BMY: Promising Phase 2 Results for Reblozyl in Alpha-Thalassemia Study - GuruFocus
Large-Cap Stock Analysis 2026: Vertiv, HCA Healthcare, Bristol-Myers SquibbNews and Statistics - IndexBox
China Universal Asset Management Co. Ltd. Purchases New Stake in Bristol Myers Squibb Company $BMY - Defense World
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? - The Motley Fool
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? - The Globe and Mail
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Barclays initiates Bristol-Myers Squibb stock coverage at overweight - Investing.com
Barclays initiates Bristol-Myers Squibb stock coverage at overweight By Investing.com - Investing.com India
ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance UK
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Finviz
Bristol Myers Squibb (NYSE:BMY) Delivers Stability While S&P 500 Stays Volatile - Kalkine Media
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma - Finviz
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Yahoo Finance
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors - ChartMill
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit - simplywall.st
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance
1.41%
0.83%
大文字化:
|
ボリューム (24 時間):